Triomics Raises $22M to Deploy Oncology AI Across Cancer Centers
Triomics, a startup building an AI-powered platform to help oncologists and administrative staff automate data-heavy tasks like clinical trial matching and appointment prep, has raised $22 million in Series B funding. The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator, and others.
The Triomics $22M oncology AI cancer centers Series B comes at a time when the complexity of cancer care is creating a growing administrative crisis. Oncology breakthroughs are keeping patients alive longer, but that welcome trend is creating dense, multi-year medical records that take healthcare staff a long time to review and decipher. A typical medical chart includes physician progress notes, imaging and pathology reports, and even scans of faxes with some records running thousands of pages.
Built for Oncology, Not Just Medicine
While generic AI agents excel at basic summaries, prominent institutions like Memorial Sloan Kettering and Yale Cancer Center use Triomics because its models are trained specifically on oncology data, giving it a meaningful edge over general-purpose tools in a high-stakes clinical environment.
Founded in 2021, Triomics raised a $15 million Series A in mid-2024, initially focused on helping doctors identify the most suitable clinical trials for their patients. Over the following two years, the platform expanded to include verifiable patient summaries as part of a broader visit-preparation workflow, surfacing key information directly within the tools clinicians already use without requiring them to switch applications. Triomics also used to automate the submission of tumor reports to government registries, a legal mandate for cancer centers.
The startup’s most direct competition comes from AI medical scribes like Abridge and Microsoft’s Nuance. Despite the crowded field, the numbers tell a compelling story. Over the past year, Triomics expanded its enterprise customer base fourfold, driving a tenfold increase in annualised recurring revenue.
With the Triomics $22M oncology AI cancer centers Series B now closed, the company positioned to deepen its footprint across major cancer institutions as demand for specialised, domain-trained clinical AI accelerates. For a broader look at how AI is reshaping healthcare administration, TechCrunch’s health tech coverage tracks the fastest-moving players in the space.
